Clinical trial NCT03298009: Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)
Official title: Subclinical Inflammation, Myocardial Function and Fatty Acid Metabolism in Patients With Type 2 Diabetes and Heart Failure: Impact of a Short-term Treatment With Canagliflozin - a Pilot Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Type2 Diabetes
Heart Failure
Lead sponsor: Université de Sherbrooke
Sponsor class: OTHER
Collaborators: name: Janssen Inc.
First posted: 2017-09-29
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Placebo-controlled, double-blind, randomized crossover 2-week intervention study.
Primary purpose: BASIC_SCIENCE

Brief summary: It is a mechanistic proof-of-concept study to demonstrate how SGLT-2 inhibitors (Canagliflozin) may have a beneficial role on cardiac energetic efficiency.

Patients with type 2 diabetes and with HF diagnosed for at least 3 months will be selected. The participants will be randomized to a double-blind, crossover 2-week placebo vs. Cana 100 mg once daily, an interventional trial with a one-month washout period in between.

At the term of the two-week placebo and canagliflozin treatment periods (visits 2 and 4), each participant will undergo an identical postprandial metabolic study with positron emission tomography (PET) and stable isotopic tracer methods.

Detailed description: Non-invasive Positron Emission Tomography (PET) imaging method allows to measure myocardial uptake and organ-specific partitioning of dietary fatty acids (DFA). It allows to study kidney, liver, skeletal muscles and adipose tissues DFA utilization, whole body fatty acid turnover and oxidation rates, myocardial oxidative metabolism and left ventricular (LV) function that are other likely targets of SGLT-2 inhibitors. Thus, the PET is ideal to verify the very interesting hypothesis that, increase in liver fatty acid utilization and/or adipose tissue dietary fatty acid uptake, may lead to reduced cardiac utilization of fatty acids and improved cardiac energetic efficiency.

.

Eligibility criteria: Inclusion Criteria:

* HbA1c 7.5 -10.5%;
* LVEF \< 40%;
* NYHA class 2 or 3;
* NT pro-BNP level \> 600 pg/mL;
* Being on a stable-dose metformin therapy max 2500 mg/day or other hypoglycemic therapy and RAAS-blocking agents for at least 8 weeks;
* Being on optimal and stable-doses of heart failure medication including diuretics for at least 4 weeks;

Exclusion Criteria:

* age \<18 yo;
* NYHA class 4;
* Treatment with a fibrate or thiazolidinedione;
* Unstable or advanced renal failure;
* Unstable or new medical or surgical condition within the past 3 months;
* Heart failure caused by active inflammatory condition such as sarcoidosis or any form of myocarditis;
* History of diabetic ketoacidosis;
* Not on a stable regimen for at least 8 weeks before the screening visit;
* Female of child-bearing potential who is pregnant, breast feeding or intends to become pregnant or pre-menopausal female with a positive serum pregnancy test at the time of enrollment;
* Patients post bariatric surgery, or on weight loss medication;
* Contraindications to metformin, including allergy or intolerance;
* Hospitalization for heart failure within the 60 days prior to enrollment;
* Admission for an acute coronary syndrome, percutaneous coronary intervention, or cardiac surgery within the 60 days prior to enrollment;
* Planned cardiovascular revascularization (percutaneous intervention or surgical) or major cardiac surgery (coronary artery bypass grafting, valve replacement, ventricular assist device, cardiac transplantation, or any other surgery requiring thoracotomy) within the 90 days after enrollment;
* Patients who are volume depleted based upon physical examination at the time of enrollment;
* Chronic disabling illness;
* History of substance abuse.

Primary outcomes:
measure: Change to be observed with canagliflozin on myocardial dietary fatty acid uptake
timeFrame: 3 months
measure: Change to be observed with canagliflozin on whole-body partitioning.
timeFrame: 3 months
Secondary outcomes:
measure: myocardial and liver NEFA uptake
timeFrame: 3 months
measure: NEFA oxidative rate
timeFrame: 3 months
measure: plasma NEFA turnover
timeFrame: 1 year
Other outcomes:
measure: Insulin sensitivity
timeFrame: 1 year
measure: Insulin secretion rate
timeFrame: 1 year
measure: β-cell function
timeFrame: 1 year
measure: hormonal response
timeFrame: 1 year
measure: Biomarkers
timeFrame: 1 year
measure: body composition
timeFrame: 3 months
Locations:
Study officials:
affiliation: Université de Sherbrooke
name: André C. Carpentier
role: PRINCIPAL_INVESTIGATOR
References: